Recommended Topic Related To:

Viramune XR

"The U.S. Food and Drug Administration today approved Tivicay (dolutegravir), a new drug to treat HIV-1 infection.

Tivicay is an integrase strand transfer inhibitor that interferes with one of the enzymes necessary for HIV to multiply. "...

Viramune XR

Overdosage
Contraindications

OVERDOSE

There is no known antidote for nevirapine overdosage. Cases of immediate-release VIRAMUNE overdose at doses ranging from 800 to 1800 mg per day for up to 15 days have been reported. Patients have experienced events including edema, erythema nodosum, fatigue, fever, headache, insomnia, nausea, pulmonary infiltrates, rash, vertigo, vomiting and weight decrease. All events subsided following discontinuation of immediate-release VIRAMUNE.

CONTRAINDICATIONS

Hepatic Impairment

VIRAMUNE XR is contraindicated in patients with moderate or severe (Child-Pugh Class B or C, respectively) hepatic impairment [see WARNINGS AND PRECAUTIONS and Use In Specific Populations].

Post-Exposure Prophylaxis

VIRAMUNE XR is contraindicated for use as part of occupational and non-occupational post-exposure prophylaxis (PEP) regimens [see WARNINGS AND PRECAUTIONS].

Last reviewed on RxList: 2/6/2014
This monograph has been modified to include the generic and brand name in many instances.

Overdosage
Contraindications
A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


WebMD Daily

Get breaking medical news.


NIH talks about Ebola on WebMD